Medtronic Cardiovascular
72
7
16
38
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
20.8%
15 terminated/withdrawn out of 72 trials
71.7%
-14.8% vs industry average
3%
2 trials in Phase 3/4
111%
42 of 38 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (72)
Medtronic Transcatheter Aortic Valve Replacement (TAVR) Low Risk Bicuspid Study
Role: lead
Safety & Efficacy Study of the Medtronic CoreValve® System-Treatment of Symptomatic Severe Aortic Stenosis With Significant Comorbidities in Extreme Risk Subjects Who Need Aortic Valve Replacement
Role: lead
Harmony TPV EMEA PMS
Role: lead
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
Role: lead
ANCHOR (Aneurysm Treatment Using the Heli-FX™ EndoAnchor™ System Global Registry)
Role: lead
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
Role: lead
Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients
Role: lead
Evolut™ EXPAND TAVR II Pivotal Trial
Role: lead
TTVR Early Feasibility Study
Role: lead
SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial
Role: lead
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
Role: lead
Transcatheter Mitral Valve Replacement System (TMVR) Pilot Study and The Early Feasibility Study of the TMVR Transseptal System
Role: lead
Optimize PRO Study
Role: lead
Transcatheter Tricuspid Valve Replacement With the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in Severe Tricuspid Regurgitation
Role: lead
Harmony TPV Post-Approval Study
Role: lead
Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial
Role: lead
Evolut PRO China Clinical Study
Role: lead
Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).
Role: lead
Endurant CHevAr New Indication Trial: ENCHANT
Role: lead
FORWARD PRO Study Interventional Post-market Study With the Evolut™ PRO System
Role: lead